Giovanna Scroccaro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Giovanna Scroccaro has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Bortolami
Area Qualità delle cure Reti e Percorsi, Settore Assistenza Ospedaliera Direzione Generale Cura della Persona, Salute e Welfare, Regione Emilia-Romagna, Bologna - Italy
2 shared publications - Giulia Pasello
Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy
2 shared publications - Pierfranco Conte
INOC - Istituto Nazionale Oncologico Candiolo; IRCCS, Candiolo, Italy
2 shared publications Alberto Bortolami
Istituto Oncologico Veneto IRCCS Padova, Padova
1 shared publication- Alberto Russi
Pharmacy Unit, IRCCS Istituto Oncologico Veneto (IOV), 35128 Padova, Italy
1 shared publication - Alessandra Buja
Department of Cardiac, Thoracic, Vascular Sciences, and Public Health, University of Padova, Padua, Italy
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 2025 (1)
Real‐Practice Analysis of Potential Antibiotic Interactions in Patients Treated With Immune Checkpoint Inhibitors: An Observational Study From an Italian Referral Cancer Center
Purpose: Inappropriate use of antibiotics contributes to the increase in antimicrobial resistance with negative health safety implications. Global health organizations have promoted projects to improve proper and rational use of antibiotics. Recent studies show how antibiotics can also influence the efficacy of immune checkpoint inhibitors (ICIs) treatment in cancer patients. This work analyzes the impact of concomitant antibiotic therapy in patients affected by skin, lung, and kidney cancer, who started immunotherapy in 2020‐2021 at Veneto Institute of Oncology IRCCS. The aim of this study is to evaluate clinical outcomes, treatment efficacy, discontinuation causes, and occurrence of adverse drug reactions in cancer patients treated with ICIs. Methods: Data from the real‐world retrospective study were extracted from Territorial Pharmaceutical Care databases, medical records, and the AIFA registry. A descriptive analysis of the study population was performed, as well as of patient outcomes in terms of progression‐free survival (PFS) and overall survival (OS). Results: A total of 239 subjects affected by kidney (8%), lung (48%), and skin (44%) cancer were enrolled; of these, 50%, 32%, 9%, and 9% were treated with single‐agent nivolumab, pembrolizumab, atezolizumab, and cemiplimab, respectively. A total of 119 patients received concomitant antibiotic therapy. Median OS was 8.8 months (95% CI: 5.02–11.8) and 31.05 months (95% CI: 24.81–NA) in subjects with high and low antibiotic exposure, respectively. Multivariate subgroup analysis confirmed that high antibiotic exposure is an unfavorable factor also for median PFS. Conclusion: A prolonged exposure to antibiotics correlates with unfavorable outcomes in cancer patients undergoing concomitant immunotherapy. Thus, managing antibiotic exposure is fundamental for optimizing ICI treatment.
- 1 January 2025
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 2025 (1)
Open AccessReal‐Practice Analysis of Potential Antibiotic Interactions in Patients Treated With Immune Checkpoint Inhibitors: An Observational Study From an Italian Referral Cancer Center
Purpose: Inappropriate use of antibiotics contributes to the increase in antimicrobial resistance with negative health safety implications. Global health organizations have promoted projects to improve proper and rational use of antibiotics. Recent studies show how antibiotics can also influence the efficacy of immune checkpoint inhibitors (ICIs) treatment in cancer patients. This work analyzes the impact of concomitant antibiotic therapy in patients affected by skin, lung, and kidney cancer, who started immunotherapy in 2020‐2021 at Veneto Institute of Oncology IRCCS. The aim of this study is to evaluate clinical outcomes, treatment efficacy, discontinuation causes, and occurrence of adverse drug reactions in cancer patients treated with ICIs. Methods: Data from the real‐world retrospective study were extracted from Territorial Pharmaceutical Care databases, medical records, and the AIFA registry. A descriptive analysis of the study population was performed, as well as of patient outcomes in terms of progression‐free survival (PFS) and overall survival (OS). Results: A total of 239 subjects affected by kidney (8%), lung (48%), and skin (44%) cancer were enrolled; of these, 50%, 32%, 9%, and 9% were treated with single‐agent nivolumab, pembrolizumab, atezolizumab, and cemiplimab, respectively. A total of 119 patients received concomitant antibiotic therapy. Median OS was 8.8 months (95% CI: 5.02–11.8) and 31.05 months (95% CI: 24.81–NA) in subjects with high and low antibiotic exposure, respectively. Multivariate subgroup analysis confirmed that high antibiotic exposure is an unfavorable factor also for median PFS. Conclusion: A prolonged exposure to antibiotics correlates with unfavorable outcomes in cancer patients undergoing concomitant immunotherapy. Thus, managing antibiotic exposure is fundamental for optimizing ICI treatment.
- Open Access
- 26 June 2023
- Published by Aboutscience Srl in Global and Regional Health Technology Assessment
- Vol. 10, 53-61
Good practices for the development of budget impact models at regional level
Introduction: The present work aims to discuss the current scenario of procedures and regulations regarding budget impact analysis/models (BIA/BIM) at regional level in Italy and to provide a standardized approach and detailed recommendations for developing these analyses. Method: A systematic review of the literature was conducted in order to collect existing guidelines or specific regional procedures for budget impact analysis in Italy. All the records were analysed in qualitative terms according to a pre-specified analytical framework, based on the ISPOR BIA guidelines. At the end of the analysis, a consensus questionnaire was developed to establish agreed approaches and to provide possible solutions to any critical issues. A list of 39 statements was developed. The survey was distributed to 69 experts who rated their level of agreement with each statement on a 5-point Likert scale. Consensus was predefined as more than 66% of the panel agreeing/disagreeing with any given statement. Results: Sisty-nine experts answered the questionnaire; a total of 30/39 statements achieved consensus. There was agreement on most of the statements. Time horizon to consider and costs were the issues on which no agreement was found. The results allowed the working group to define a list of good practices. Conclusion: While the structure and development of BIM are now well-known and well-applied at national level, there remains a great diversity of management of BIM tools at regional level. Consensus was reached among participating experts, as to the main characteristics, determinants and features of regional BIA/BIM in the perspective of the Italian payer.
- 26 June 2023
- Published by Aboutscience Srl in Global and Regional Health Technology Assessment
- Vol. 10, 53-61
Open AccessGood practices for the development of budget impact models at regional level
Introduction: The present work aims to discuss the current scenario of procedures and regulations regarding budget impact analysis/models (BIA/BIM) at regional level in Italy and to provide a standardized approach and detailed recommendations for developing these analyses. Method: A systematic review of the literature was conducted in order to collect existing guidelines or specific regional procedures for budget impact analysis in Italy. All the records were analysed in qualitative terms according to a pre-specified analytical framework, based on the ISPOR BIA guidelines. At the end of the analysis, a consensus questionnaire was developed to establish agreed approaches and to provide possible solutions to any critical issues. A list of 39 statements was developed. The survey was distributed to 69 experts who rated their level of agreement with each statement on a 5-point Likert scale. Consensus was predefined as more than 66% of the panel agreeing/disagreeing with any given statement. Results: Sisty-nine experts answered the questionnaire; a total of 30/39 statements achieved consensus. There was agreement on most of the statements. Time horizon to consider and costs were the issues on which no agreement was found. The results allowed the working group to define a list of good practices. Conclusion: While the structure and development of BIM are now well-known and well-applied at national level, there remains a great diversity of management of BIM tools at regional level. Consensus was reached among participating experts, as to the main characteristics, determinants and features of regional BIA/BIM in the perspective of the Italian payer.
- 1 July 2022
- Published by Il Pensiero Scientifico Editore in Recenti Progressi in Medicina
- Vol. 113 (7) , 440-450
L’impatto dell’uso dei trattamenti non compresi nelle classi di rimborsabilità nella presa in carico dei malati rari: uno studio in campo reale
Introduzione. Il trattamento delle malattie rare non si avvale solamente di farmaci orfani, ma di molteplici strategie di trattamento. Questo studio su popolazione analizza i trattamenti essenziali e non sostituibili prescritti a questi malati, anche se non direttamente a carico del Sistema Sanitario Nazionale (SSN), in risposta a bisogni terapeutici specifici e individuali, allo scopo di valutare come essi incidano sull’effettiva e reale presa in carico. Metodi. Per il biennio 2019-2020, sono state esaminate le prescrizioni di prodotti indispensabili non direttamente rimborsati dal SSN presenti nei piani terapeutici per pazienti residenti nella Regione del Veneto (4,9 milioni di abitanti) utilizzando la fonte Registro regionale delle malattie rare e stimando le spese sostenute per erogarli. Risultati. Le prescrizioni di trattamenti per malati rari residenti non direttamente rimborsate dal SSN sono state, nel biennio considerato, 22.186, distribuite in 9197 piani di trattamento. Tali prescrizioni sono trasversali ai vari gruppi di malattie rare. L’11% dei piani ha 5 o più di queste prescrizioni. Tra i 3041 diversi prodotti utilizzati dai malati rari, la quota relativa a farmaci è pari al 41%. La spesa regionale sostenuta per l’erogazione di questa complessità di farmaci e altri prodotti rivela che solo pochi farmaci, i primi 10 per volume di spesa, impattano per oltre il 50% della spesa regionale. La spesa annuale complessivamente sostenuta per tutto questo comparto prescrittivo resta comunque globalmente contenuta, e nella Regione del Veneto è di poco superiore a 1 milione di euro per milione di abitanti. Conclusioni. Questo studio in campo reale analizza quale sia il livello di complessità e di accessibilità a trattamenti indispensabili prescritti a un consistente numero di pazienti con malattia rara. I piani di trattamento sono complessi, componendosi di molteplici trattamenti, anche al di fuori dell’esplicita rimborsabilità del SSN. L’uso di registri di popolazione che forniscono dati real-world è fondamentale per capire i reali bisogni terapeutici dei malati rari, favorire l’accessibilità ai trattamenti indispensabili ed essenziali e valutare il loro impatto sulla spesa farmaceutica globale.
- 1 July 2022
- Published by Il Pensiero Scientifico Editore in Recenti Progressi in Medicina
- Vol. 113 (7) , 440-450
L’impatto dell’uso dei trattamenti non compresi nelle classi di rimborsabilità nella presa in carico dei malati rari: uno studio in campo reale
Introduzione. Il trattamento delle malattie rare non si avvale solamente di farmaci orfani, ma di molteplici strategie di trattamento. Questo studio su popolazione analizza i trattamenti essenziali e non sostituibili prescritti a questi malati, anche se non direttamente a carico del Sistema Sanitario Nazionale (SSN), in risposta a bisogni terapeutici specifici e individuali, allo scopo di valutare come essi incidano sull’effettiva e reale presa in carico. Metodi. Per il biennio 2019-2020, sono state esaminate le prescrizioni di prodotti indispensabili non direttamente rimborsati dal SSN presenti nei piani terapeutici per pazienti residenti nella Regione del Veneto (4,9 milioni di abitanti) utilizzando la fonte Registro regionale delle malattie rare e stimando le spese sostenute per erogarli. Risultati. Le prescrizioni di trattamenti per malati rari residenti non direttamente rimborsate dal SSN sono state, nel biennio considerato, 22.186, distribuite in 9197 piani di trattamento. Tali prescrizioni sono trasversali ai vari gruppi di malattie rare. L’11% dei piani ha 5 o più di queste prescrizioni. Tra i 3041 diversi prodotti utilizzati dai malati rari, la quota relativa a farmaci è pari al 41%. La spesa regionale sostenuta per l’erogazione di questa complessità di farmaci e altri prodotti rivela che solo pochi farmaci, i primi 10 per volume di spesa, impattano per oltre il 50% della spesa regionale. La spesa annuale complessivamente sostenuta per tutto questo comparto prescrittivo resta comunque globalmente contenuta, e nella Regione del Veneto è di poco superiore a 1 milione di euro per milione di abitanti. Conclusioni. Questo studio in campo reale analizza quale sia il livello di complessità e di accessibilità a trattamenti indispensabili prescritti a un consistente numero di pazienti con malattia rara. I piani di trattamento sono complessi, componendosi di molteplici trattamenti, anche al di fuori dell’esplicita rimborsabilità del SSN. L’uso di registri di popolazione che forniscono dati real-world è fondamentale per capire i reali bisogni terapeutici dei malati rari, favorire l’accessibilità ai trattamenti indispensabili ed essenziali e valutare il loro impatto sulla spesa farmaceutica globale.
- 1 August 2021
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 17 (8) , e1085-e1093
Non–Small-Cell Lung Cancer: Real-World Cost Consequence Analysis
PURPOSE: The present work aimed at conducting a real-world data analysis on the management costs and survival analysis comparing data from non–small-cell lung cancer (NSCLC) cases diagnosed in the Veneto region before (2015) and after (2017) the implementation of a regional diagnostic and therapeutic pathway including all new diagnostic and therapeutic strategies.METHOD: This study considered 254 incidental cases of NSCLC in 2015 and 228 in 2017 within the territory of the Padua province (Italy), as recorded by the Veneto Cancer Registry. Tobit regression analysis was performed to verify if total and each item costs (2 years after NSCLC diagnosis) are associated with index year, adjusting by year of diagnosis, sex, age, and stage at diagnosis. Logistic regression models were run to study overall mortality at 2 years, adjusting by the same covariates.RESULTS: The 2017 cohort had a lower mortality odd (odds ratio, 0.93; P = .02) and a significant increase in the average overall costs ( P = .009) than the 2015 cohort. The Tobit regression analysis by cost item showed a very significant increase in the average cost of drugs (coefficient = 5,953, P = .008) for the 2017 cohort, as well as a decrease in the average cost of hospice care (coefficient = –1,822.6, P = .022).CONCLUSION: Our study showed a survival improvement for patients with NSCLC as well as an economic burden growth. Physicians should therefore be encouraged to follow new clinical care pathways, while the steadily rising related costs underscore the need for policymakers and health professionals to pursue.
- 1 August 2021
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 17 (8) , e1085-e1093
Non–Small-Cell Lung Cancer: Real-World Cost Consequence Analysis
PURPOSE: The present work aimed at conducting a real-world data analysis on the management costs and survival analysis comparing data from non–small-cell lung cancer (NSCLC) cases diagnosed in the Veneto region before (2015) and after (2017) the implementation of a regional diagnostic and therapeutic pathway including all new diagnostic and therapeutic strategies.METHOD: This study considered 254 incidental cases of NSCLC in 2015 and 228 in 2017 within the territory of the Padua province (Italy), as recorded by the Veneto Cancer Registry. Tobit regression analysis was performed to verify if total and each item costs (2 years after NSCLC diagnosis) are associated with index year, adjusting by year of diagnosis, sex, age, and stage at diagnosis. Logistic regression models were run to study overall mortality at 2 years, adjusting by the same covariates.RESULTS: The 2017 cohort had a lower mortality odd (odds ratio, 0.93; P = .02) and a significant increase in the average overall costs ( P = .009) than the 2015 cohort. The Tobit regression analysis by cost item showed a very significant increase in the average cost of drugs (coefficient = 5,953, P = .008) for the 2017 cohort, as well as a decrease in the average cost of hospice care (coefficient = –1,822.6, P = .022).CONCLUSION: Our study showed a survival improvement for patients with NSCLC as well as an economic burden growth. Physicians should therefore be encouraged to follow new clinical care pathways, while the steadily rising related costs underscore the need for policymakers and health professionals to pursue.
- 1 April 2008
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 42 (4) , 373-380
Risk Factors of Peptic Ulcer in 4943 Inpatients
Over the past few years, major changes have taken place in the treatment of gastroduodenal peptic ulcer. To evaluate risk factors associated with the incidence of peptic ulcer in inpatients. From 2001 to 2004, the number of prescriptions of H2-antagonists and proton pump inhibitors (PPIs) in each department of Verona University Hospital was monitored. Over the same period we prospectively recorded the number of upper endoscopies per department for inpatients with a diagnosis of peptic ulcer. We analyzed 4943 inpatients. A significantly decreasing trend in H(2)-antagonist prescriptions (r=-0,88; P<0.001) and an increasing trend in PPI prescriptions (r=0.97; P<0.001) were observed. The endoscopic incidence of duodenal ulcers decreased linearly from 2001 to 2004 as follows: 6.5% (94/1439) in 2001, 5.6% (82/1473) in 2002, 4.5% (63/1411) in 2003, and 3.1% (22/702) (P<0.001) in 2004. Gastric ulcer incidence, sex, age, indication for endoscopy, use of nonsteroidal anti-inflammatory drugs (NSAIDs), presence of Helicobacter pylori (32%), and smoking and drinking habits showed no significant changes over the study period. Considering time-dependent variables, multivariate regression analysis identified only PPI use and NSAID use as factors predictive of duodenal ulcer but not of gastric ulcer. In inpatients, PPIs are associated with a reduced risk of duodenal ulcer, whereas NSAIDs are associated with an increased risk. Gastric ulcer was not associated with any increased or degreased risk with the 2 above-mentioned variables.
- 1 April 2008
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 42 (4) , 373-380
Risk Factors of Peptic Ulcer in 4943 Inpatients
Over the past few years, major changes have taken place in the treatment of gastroduodenal peptic ulcer. To evaluate risk factors associated with the incidence of peptic ulcer in inpatients. From 2001 to 2004, the number of prescriptions of H2-antagonists and proton pump inhibitors (PPIs) in each department of Verona University Hospital was monitored. Over the same period we prospectively recorded the number of upper endoscopies per department for inpatients with a diagnosis of peptic ulcer. We analyzed 4943 inpatients. A significantly decreasing trend in H(2)-antagonist prescriptions (r=-0,88; P<0.001) and an increasing trend in PPI prescriptions (r=0.97; P<0.001) were observed. The endoscopic incidence of duodenal ulcers decreased linearly from 2001 to 2004 as follows: 6.5% (94/1439) in 2001, 5.6% (82/1473) in 2002, 4.5% (63/1411) in 2003, and 3.1% (22/702) (P<0.001) in 2004. Gastric ulcer incidence, sex, age, indication for endoscopy, use of nonsteroidal anti-inflammatory drugs (NSAIDs), presence of Helicobacter pylori (32%), and smoking and drinking habits showed no significant changes over the study period. Considering time-dependent variables, multivariate regression analysis identified only PPI use and NSAID use as factors predictive of duodenal ulcer but not of gastric ulcer. In inpatients, PPIs are associated with a reduced risk of duodenal ulcer, whereas NSAIDs are associated with an increased risk. Gastric ulcer was not associated with any increased or degreased risk with the 2 above-mentioned variables.